State Street’s DiaMedica Therapeutics DMAC Stock Holding History

State Street’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.55M	Buy	646,743 +2,532	+0.4%	+$15.6K	﹤0.01%	3057
2026 Q1	$4.36M	Buy	644,211 +16,440	+3%	+$130K	﹤0.01%	3014
2025 Q4	$5M	Buy	627,771 +151,188	+32%	+$1.13M	﹤0.01%	2993
2025 Q3	$3.27M	Buy	476,583 +224,635	+89%	+$1.22M	﹤0.01%	3164
2025 Q2	$983K	Buy	251,948 +166,919	+196%	+$651K	﹤0.01%	3488
2025 Q1	$322K	Hold	85,029	–	–	﹤0.01%	3711
2024 Q4	$462K	Buy	85,029 +16,300	+24%	+$76.9K	﹤0.01%	3639
2024 Q3	$288K	Hold	68,729	–	–	﹤0.01%	3733
2024 Q2	$203K	Buy	68,729 +2,100	+3%	+$5.76K	﹤0.01%	3825
2024 Q1	$185K	Hold	66,629	–	–	﹤0.01%	3889
2023 Q4	$189K	Hold	66,629	–	–	﹤0.01%	3913
2023 Q3	$172K	Hold	66,629	–	–	﹤0.01%	3978
2023 Q2	$288K	Hold	66,629	–	–	﹤0.01%	3888
2023 Q1	$102K	Hold	66,629	–	–	﹤0.01%	4320
2022 Q4	$105K	Hold	66,629	–	–	﹤0.01%	4357
2022 Q3	$83K	Hold	66,629	–	–	﹤0.01%	4527
2022 Q2	$135K	Hold	66,629	–	–	﹤0.01%	4375
2022 Q1	$167K	Buy	66,629 +6,912	+12%	+$19.6K	﹤0.01%	4449
2021 Q4	$223K	Buy	59,717 +20,000	+50%	+$78.5K	﹤0.01%	4303
2021 Q3	$159K	Buy	39,717 +9,500	+31%	+$36.4K	﹤0.01%	4428
2021 Q2	$134K	Buy	+30,217	New	+$248K	﹤0.01%	4307

Other funds holding DMAC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Members Wealth Media, Pennsylvania $182M AUM 15.09% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

MWM

Meridian Wealth Management Lexington, Kentucky $3.25B AUM 41% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

CFP

Catalyst Financial Partners Boston, Massachusetts $1.01B AUM 36.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

State Street's DMAC Position: Q2 2026 in Review

State Street increased its DiaMedica Therapeutics (DMAC) stake by 0.39% in Q2 2026, buying an estimated $15.6K and bringing the position to 646,743 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3057.

State Street first reported a position in DMAC in Q2 2021 and has held it in 21 quarters since. The position peaked at $5M in Q4 2025. 30 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

State Street held 646,743 shares of DiaMedica Therapeutics worth $4.55M as of Q2 2026.
State Street bought 2,532 DiaMedica Therapeutics shares in Q2 2026, an estimated $15.6K.
DiaMedica Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3057 holding.
State Street first reported a position in DiaMedica Therapeutics in Q2 2021 and has held it in 21 quarters since.
State Street's DiaMedica Therapeutics position peaked at $5M in Q4 2025.
30 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.